Literature DB >> 2302005

Effects of patient age and physician training on choice and dose of benzodiazepine hypnotic drugs.

R I Shorr1, S F Bauwens.   

Abstract

We conducted a cross-sectional review of all prescriptions (N = 554) for triazolam and flurazepam hydrochloride written by nonpsychiatrists to outpatients at a university affiliated Veterans Administration hospital. We sought to determine whether triazolam, an agent with a short half-life, was used preferentially in older patients (age greater than or equal to 70 years). We also wanted to determine whether dosages of triazolam or flurazepam were lowered in elderly patients. Our findings showed that prescriber level of training was a much stronger determinant of drug choice than patient age. Attending physicians prescribed flurazepam twice as often as interns. Lower dosages of both agents were prescribed more frequently to older patients. Our data suggest that some physicians choose a benzodiazepine hypnotic out of habit rather than application of pharmacologic principles, but reduce doses appropriately when prescribing to elderly patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302005

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  Recent advances in geriatric psychopharmacology.

Authors:  C A Naranjo; N Herrmann; N Mittmann; K E Bremner
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

Review 2.  Adverse drug reactions in elderly patients.

Authors:  P A Routledge; M S O'Mahony; K W Woodhouse
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

3.  Relation between physician characteristics and prescribing for elderly people in New Brunswick.

Authors:  W Davidson; D W Molloy; G Somers; M Bédard
Journal:  CMAJ       Date:  1994-03-15       Impact factor: 8.262

4.  High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates.

Authors:  M Y Egan; C Wolfson; Y Moride; J Monette
Journal:  BMC Geriatr       Date:  2001       Impact factor: 3.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.